CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors
Emmanuel S. Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L. Maughan, Roberto Pili, Nabil Adra, Cora N. Sternberg, Panagiotis J. Vlachostergios, Scott T. Tagawa, Alan H. Bryce, Andrea L. McNatty, Zachery R. Reichert, Robert Dreicer, Oliver Sartor, Tamara L. Lotan, Maha Hussain
Dive into the research topics of 'CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors'. Together they form a unique fingerprint.